298 related articles for article (PubMed ID: 22876543)
41. Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta.
Lin HY; Lin SP; Chuang CK; Chen MR; Chang CY
Pediatr Neonatol; 2008 Oct; 49(5):161-5. PubMed ID: 19133566
[TBL] [Abstract][Full Text] [Related]
42. Dental panoramic indices and fractal dimension measurements in osteogenesis imperfecta children under pamidronate treatment.
Apolinário AC; Sindeaux R; de Souza Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; de Paula AP; de Paula LM; de Melo NS; Leite AF
Dentomaxillofac Radiol; 2016; 45(4):20150400. PubMed ID: 26954289
[TBL] [Abstract][Full Text] [Related]
43. [Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].
Yamashita S
Clin Calcium; 2010 Jun; 20(6):918-24. PubMed ID: 20513950
[TBL] [Abstract][Full Text] [Related]
44. Treatment of symptomatic osteoporosis in children: a comparison of two pamidronate dosage regimens.
Martinez-Soto T; Pacaud D; Stephure D; Trussell R; Huang C
J Pediatr Endocrinol Metab; 2011; 24(5-6):271-4. PubMed ID: 21823522
[TBL] [Abstract][Full Text] [Related]
45. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
46. Therapy with pamidronate in children with osteogenesis imperfecta.
Marginean O; Tamasanu RC; Mang N; Mozos I; Brad GF
Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and Safety of Denosumab vs Zoledronic Acid in OI Adults: A Prospective, Open-Label, Randomized Study.
Lin X; Hu J; Zhou B; Wang X; Zhang Q; Jiang Y; Wang O; Xia W; Xing X; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1873-1882. PubMed ID: 38181430
[TBL] [Abstract][Full Text] [Related]
49. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
50. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
Choi JH; Shin YL; Yoo HW
J Korean Med Sci; 2007 Apr; 22(2):209-12. PubMed ID: 17449925
[TBL] [Abstract][Full Text] [Related]
51. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
Apolinário AC; Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; Paula AP; Paula LM; Melo NS; Leite AF
J Dent Res; 2015 Mar; 94(3 Suppl):95S-102S. PubMed ID: 25608973
[TBL] [Abstract][Full Text] [Related]
52. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
[TBL] [Abstract][Full Text] [Related]
53. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
Zacharin M; Bateman J
J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
[TBL] [Abstract][Full Text] [Related]
55. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
Feehan AG; Zacharin MR; Lim AS; Simm PJ
Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
[TBL] [Abstract][Full Text] [Related]
56. The long-term effects of switching from active intravenous bisphosphonate treatment to low-dose maintenance therapy in children with osteogenesis imperfecta.
Biggin A; Zheng L; Briody JN; Coorey CP; Munns CF
Horm Res Paediatr; 2015; 83(3):183-9. PubMed ID: 25676713
[TBL] [Abstract][Full Text] [Related]
57. Two doses of pamidronate in infants with osteogenesis imperfecta.
Senthilnathan S; Walker E; Bishop NJ
Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta.
González E; Pavía C; Ros J; Villaronga M; Valls C; Escolá J
J Pediatr Endocrinol Metab; 2001 May; 14(5):529-33. PubMed ID: 11393574
[TBL] [Abstract][Full Text] [Related]
59. Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta.
Lin CH; Chien YH; Peng SF; Tsai WY; Tung YC; Lee CT; Chien CC; Hwu WL; Lee NC
Pediatr Neonatol; 2014 Aug; 55(4):306-11. PubMed ID: 24486247
[TBL] [Abstract][Full Text] [Related]
60. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
Zacharin M; Kanumakala S
J Pediatr Endocrinol Metab; 2004 Nov; 17(11):1511-7. PubMed ID: 15570988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
